This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.
Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40.98% and 87.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
by Zacks Equity Research
Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.
Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.
Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -11.86% and -67.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
by Zacks Equity Research
Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
Frontier Communications' (FTR) Q4 Earnings: What's in Store?
by Zacks Equity Research
Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.
Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
by Zacks Equity Research
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.
What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
by Zacks Equity Research
Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.
Why Is Theravance Bio (TBPH) Up 17.9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
by Zacks Equity Research
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
by Zacks Equity Research
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 6.78% and 21.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Up as CHMP Backs Trelegy Elipta Line Extension
by Zacks Equity Research
Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.